Meta-Analysis Reinforces Link Between SSRIs and Sexual Dysfunction in Adults With Depression
Key Clinical Summary
- Selective serotonin reuptake inhibitors (SSRIs) significantly increased risk of orgasmic dysfunction vs placebo (RR 3.28; 95% CI, 2.33–4.60; I²=8%) in adults with depression in a recent meta-analysis.
- Reduced sexual satisfaction was also observed (RR 1.21; 95% CI, 1.11–1.32; I²=0%).
- Evidence certainty ranged from high (orgasmic dysfunction) to moderate for other sexual outcomes.
Selective serotonin reuptake inhibitors (SSRIs) are associated with a significantly increased risk of sexual dysfunction in adults treated for depression, according to a systematic review and meta-analysis published in the European Journal of Clinical Pharmacology. The analysis found robust evidence linking SSRIs to orgasmic dysfunction and reduced sexual satisfaction compared with placebo.
Study Findings
Researchers conducted a systematic search of PubMed/MEDLINE, LILACS, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published through June 2025. Eligible studies involved participants aged 18 years or older with a confirmed diagnosis of depression in whom SSRIs were initiated after randomization. All included studies assessed differences in sexual dysfunction outcomes in those receiving SSRIs and a comparator arm receiving either placebo or no SSRI therapy.
Thirteen RCTs met criteria for qualitative synthesis, and 6 were included in quantitative meta-analyses. Both dichotomous and continuous outcomes were analyzed using RevMan 5.4, with 95% confidence intervals. Risk of bias was independently assessed by 2 reviewers using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2).
Compared with placebo, SSRIs were significantly associated with orgasmic dysfunction (risk ratio [RR] 3.28; 95% CI, 2.33–4.60; p < 0.00001; I²=8%). Reduced sexual satisfaction was also significantly more common among SSRI users (RR 1.21; 95% CI, 1.11–1.32; p = 0.0001; I²=0%).
A non-significant trend toward decreased sexual desire was also observed (RR 1.40; 95% CI, 0.92–2.12; p = 0.12; I²=54%). Compared with placebo, there were no significant differences detected in total scores on the Changes in Sexual Functioning Questionnaire (CSFQ).
Using GRADE methodology, investigators rated the certainty of evidence as high for orgasmic dysfunction. Evidence was rated as moderate for sexual satisfaction, sexual desire disorders, and total CSFQ scores, primarily due to risk-of-bias considerations.
Clinical Implications
Sexual dysfunction remains a clinically significant adverse effect of SSRI therapy in adults with depression. The more than threefold increased risk of orgasmic dysfunction highlights a potential barrier to treatment adherence and quality of life.
Although overall CSFQ scores did not differ significantly from placebo, specific domains were adversely affected, underscoring the importance of proactively discussing sexual side effects when initiating SSRI therapy. Awareness of differential effects across sexual domains may inform individualized treatment strategies, including consideration of alternative antidepressants or dose adjustments when clinically appropriate.
Expert Commentary
“These findings underscore the importance of systematic sexual function assessment and monitoring in patients receiving SSRI treatment,” wrote first author Sarah Dagostin Ferraz, MS Candidate, and senior author Maria Inês da Rosa, PhD, both of the Translational Biomedicine Laboratory, Graduate Program in Health Sciences, Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, Brazil, and coauthors. “Healthcare providers should engage in open discussions about sexual side effects, consider alternative treatments when appropriate, and implement management strategies to preserve patients’ sexual health and overall quality of life.”
The authors emphasized that future research should investigate the comparative effects across SSRI agents and identify predictors of sexual dysfunction susceptibility to better inform targeted, personalized treatment approaches.